Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR) Shares Purchased by Wells Fargo & Company MN

Wells Fargo & Company MN increased its position in shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 43.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 62,886 shares of the biotechnology company's stock after purchasing an additional 18,933 shares during the period. Wells Fargo & Company MN owned 0.05% of Arrowhead Pharmaceuticals worth $1,182,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. R Squared Ltd bought a new stake in shares of Arrowhead Pharmaceuticals during the fourth quarter valued at approximately $38,000. Van ECK Associates Corp increased its holdings in Arrowhead Pharmaceuticals by 72.3% in the 4th quarter. Van ECK Associates Corp now owns 2,978 shares of the biotechnology company's stock valued at $56,000 after acquiring an additional 1,250 shares during the last quarter. KBC Group NV lifted its stake in Arrowhead Pharmaceuticals by 45.9% in the 4th quarter. KBC Group NV now owns 5,224 shares of the biotechnology company's stock worth $98,000 after purchasing an additional 1,644 shares in the last quarter. Envestnet Portfolio Solutions Inc. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $190,000. Finally, First Citizens Bank & Trust Co. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter valued at about $205,000. Hedge funds and other institutional investors own 62.61% of the company's stock.

Insiders Place Their Bets

In other news, CEO Christopher Richard Anzalone sold 40,322 shares of the business's stock in a transaction that occurred on Wednesday, April 9th. The shares were sold at an average price of $10.07, for a total value of $406,042.54. Following the sale, the chief executive officer now directly owns 4,022,055 shares of the company's stock, valued at approximately $40,502,093.85. The trade was a 0.99 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 275,880 shares of company stock valued at $4,034,037 over the last ninety days. Company insiders own 4.30% of the company's stock.

Wall Street Analyst Weigh In

A number of research firms recently commented on ARWR. Chardan Capital reiterated a "buy" rating and issued a $60.00 target price on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. B. Riley reiterated a "buy" rating and set a $38.00 target price (down from $51.00) on shares of Arrowhead Pharmaceuticals in a research report on Friday, February 14th. HC Wainwright restated a "buy" rating and issued a $80.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Wednesday, February 12th. Finally, Royal Bank of Canada reiterated an "outperform" rating and set a $42.00 price objective on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, February 11th. One research analyst has rated the stock with a sell rating, four have given a hold rating and six have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of "Hold" and an average price target of $41.44.

Arrowhead Pharmaceuticals Price Performance

ARWR traded up $0.57 on Friday, reaching $14.61. 942,259 shares of the company's stock were exchanged, compared to its average volume of 1,447,267. The stock has a market cap of $2.01 billion, a PE ratio of -2.82 and a beta of 0.99. The company has a debt-to-equity ratio of 7.27, a current ratio of 6.09 and a quick ratio of 6.09. Arrowhead Pharmaceuticals, Inc. has a twelve month low of $9.57 and a twelve month high of $30.41. The stock's fifty day moving average price is $14.06 and its 200-day moving average price is $18.27.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The biotechnology company reported ($1.39) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.42) by ($0.97). Sell-side analysts expect that Arrowhead Pharmaceuticals, Inc. will post -2.42 EPS for the current year.

Arrowhead Pharmaceuticals Company Profile

Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases.